Curious to see your top suppliers emissions?
Book a demo for a pilot project
Book a demo for a pilot project
Genzyme Corporation, Inc., a prominent player in the biotechnology industry, is headquartered in the United States. Founded in 1981, Genzyme has established itself as a leader in developing innovative therapies for rare genetic disorders, multiple sclerosis, and other serious conditions. The company operates primarily in North America and Europe, focusing on areas such as enzyme replacement therapy and gene therapy.
Genzyme's core products, including Cerezyme and Fabrazyme, are distinguished by their ability to address unmet medical needs, providing patients with life-altering treatments. With a strong commitment to research and development, Genzyme has achieved significant milestones, including its acquisition by Sanofi in 2011, which further solidified its market position. Renowned for its dedication to patient care and scientific advancement, Genzyme continues to make a meaningful impact in the biopharmaceutical landscape.
+60 vs industry average
Genzyme Corporation, Inc.’s score of 100 is higher than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Pharmaceutical Preparation Manufacturing is among the least carbon-intensive industries
The Pharmaceutical Preparation Manufacturing industry has increased its overall emissions by 132% since 0
No reported emissions data is available for Genzyme Corporation, Inc. yet.
Genzyme Corporation, Inc., headquartered in the US, currently does not have specific carbon emissions data available for recent years. As a current subsidiary of Sanofi, any climate commitments or emissions data may be influenced by the parent company's initiatives.
Sanofi has set ambitious targets for carbon reduction, which are cascaded down to Genzyme. These include commitments to the Science Based Targets initiative (SBTi) and participation in the CDP (formerly the Carbon Disclosure Project). However, specific reduction targets or achievements for Genzyme itself have not been disclosed.
The company is also aligned with the RE100 initiative, aiming for 100% renewable electricity, and is involved in the Race to Zero campaign, which focuses on achieving net-zero emissions. While Genzyme has not published its own emissions figures, it is expected to adhere to the broader climate strategies established by Sanofi, reflecting a commitment to sustainability and climate action within the biopharmaceutical industry.
Access structured emission data, company specific factors and auditable source documents
No climate goals have been disclosed for Genzyme Corporation, Inc. yet.
No scope 3 category breakdown has been disclosed yet.


No peer comparison is available for Genzyme Corporation, Inc. yet.
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn more